The potential for targeted rewriting of epigenetic marks in COPD as a new therapeutic approach

Dan-Dan Wu, Juan Song, Sabine Bartel, Susanne Krauss-Etschmann, Marianne G. Rots, Machteld N. Hylkema

PII: S0163-7258(17)30217-6
DOI: doi:10.1016/j.pharmthera.2017.08.007
Reference: JPT 7117

To appear in: *Pharmacology and Therapeutics*

Please cite this article as: Wu, D.-D., Song, J., Bartel, S., Krauss-Etschmann, S., Rots, M.G. & Hylkema, M.N., The potential for targeted rewriting of epigenetic marks in COPD as a new therapeutic approach, *Pharmacology and Therapeutics* (2017), doi:10.1016/j.pharmthera.2017.08.007

P&T 22942

The potential for targeted rewriting of epigenetic marks in COPD as a new therapeutic approach.

Dan-Dan Wu[1,2,3], Juan Song[1,2,4], Sabine Bartel[5], Susanne Krauss-Etschmann[5], Marianne G. Rots[1] and Machteld N. Hylkema[1,2]

[1]University of Groningen, University Medical Center Groningen, Department of Pathology and Medical Biology, Groningen, The Netherlands.

[2]University of Groningen, University Medical Center Groningen, GRIAC Research Institute, Groningen, The Netherlands.

[3]Laboratory of Cancer Biology and Epigenetics, Department of Cell Biology and Genetics, Shantou University Medical College, Shantou, Guangdong, P. R. China.

[4]Tianjin Medical University, School of Basic Medical Sciences, Department of Biochemistry and Molecular Biology, Department of Immunology, Tianjin, China

[5]Priority Area Asthma & Allergy, Leibnitz Center for Medicine and Biosciences, Research Center Borstel and Christian Albrechts University Kiel, Germany; Airway Research Center North, member of the German Center for Lung Research.

Corresponding author

Machteld N. Hylkema

University Medical Center Groningen,

Department of Pathology and Medical Biology, EA10

Hanzeplein 1, 9713 GZ, Groningen, The Netherlands.

m.n.hylkema@umcg.nl